Practice patterns of SGO members for stage IIIA endometrial cancer

Christine M. Lee, Brian Slomovitz, Marilyn Greer, Sheena Sharma, Mary Ann Gregurich, Thomas Burke, Karen H. Lu, Lois M. Ramondetta

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective. The purpose of surgical staging is to better determine prognosis and treatment. The International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer is a heterogenous disease, and adjuvant therapy is not well-defined. The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer. Methods. All 850 members of the SGO were mailed surveys that asked how they would manage various case scenarios of stage IIIA endometrial cancer. Data were collected using an Internet survey database. Frequency distributions were determined, and nonparametric tests were performed. Results. Fifty-three percent of SGO members and fellows responded. For the treatment of stage IIIA disease with malignant cytology only, adjuvant therapy was recommended 46%, 62%, and 98% of the time for women with grades 1, 2, and UPSC, respectively. Sixty-six percent of respondents would not remove malignant cytology from the current staging criteria. Ninety-nine percent of respondents recommended adjuvant therapy for patients with adnexal or serosal involvement. Eighty-six percent indicated that a hysteroscopy for diagnosis would not alter their treatment recommendations. Conclusions. While most gynecologic oncologists in our survey recommend adjuvant therapy for stage IIIA endometrial carcinoma, our results showed that patients with malignant cytology only would receive different treatments than patients with adenxal or serosal involvement. Histology and grade of the tumor are predictors of therapy recommendations over malignant cytology. Most respondents agreed that patients with malignant cytology should remain in stage IIIA.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalGynecologic Oncology
Volume98
Issue number1
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Cell Biology
Therapeutics
Oncologists
Hysteroscopy
Surveys and Questionnaires
Gynecology
Internet
Obstetrics
Histology
Databases

Keywords

  • Adjuvant therapy
  • Cytology
  • Endometrial cancer
  • Stage IIIA

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Lee, C. M., Slomovitz, B., Greer, M., Sharma, S., Gregurich, M. A., Burke, T., ... Ramondetta, L. M. (2005). Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecologic Oncology, 98(1), 77-83. https://doi.org/10.1016/j.ygyno.2005.03.033

Practice patterns of SGO members for stage IIIA endometrial cancer. / Lee, Christine M.; Slomovitz, Brian; Greer, Marilyn; Sharma, Sheena; Gregurich, Mary Ann; Burke, Thomas; Lu, Karen H.; Ramondetta, Lois M.

In: Gynecologic Oncology, Vol. 98, No. 1, 07.2005, p. 77-83.

Research output: Contribution to journalArticle

Lee, CM, Slomovitz, B, Greer, M, Sharma, S, Gregurich, MA, Burke, T, Lu, KH & Ramondetta, LM 2005, 'Practice patterns of SGO members for stage IIIA endometrial cancer', Gynecologic Oncology, vol. 98, no. 1, pp. 77-83. https://doi.org/10.1016/j.ygyno.2005.03.033
Lee, Christine M. ; Slomovitz, Brian ; Greer, Marilyn ; Sharma, Sheena ; Gregurich, Mary Ann ; Burke, Thomas ; Lu, Karen H. ; Ramondetta, Lois M. / Practice patterns of SGO members for stage IIIA endometrial cancer. In: Gynecologic Oncology. 2005 ; Vol. 98, No. 1. pp. 77-83.
@article{4b0314f2bdf44d11a337ed4cc4406a0b,
title = "Practice patterns of SGO members for stage IIIA endometrial cancer",
abstract = "Objective. The purpose of surgical staging is to better determine prognosis and treatment. The International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer is a heterogenous disease, and adjuvant therapy is not well-defined. The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer. Methods. All 850 members of the SGO were mailed surveys that asked how they would manage various case scenarios of stage IIIA endometrial cancer. Data were collected using an Internet survey database. Frequency distributions were determined, and nonparametric tests were performed. Results. Fifty-three percent of SGO members and fellows responded. For the treatment of stage IIIA disease with malignant cytology only, adjuvant therapy was recommended 46{\%}, 62{\%}, and 98{\%} of the time for women with grades 1, 2, and UPSC, respectively. Sixty-six percent of respondents would not remove malignant cytology from the current staging criteria. Ninety-nine percent of respondents recommended adjuvant therapy for patients with adnexal or serosal involvement. Eighty-six percent indicated that a hysteroscopy for diagnosis would not alter their treatment recommendations. Conclusions. While most gynecologic oncologists in our survey recommend adjuvant therapy for stage IIIA endometrial carcinoma, our results showed that patients with malignant cytology only would receive different treatments than patients with adenxal or serosal involvement. Histology and grade of the tumor are predictors of therapy recommendations over malignant cytology. Most respondents agreed that patients with malignant cytology should remain in stage IIIA.",
keywords = "Adjuvant therapy, Cytology, Endometrial cancer, Stage IIIA",
author = "Lee, {Christine M.} and Brian Slomovitz and Marilyn Greer and Sheena Sharma and Gregurich, {Mary Ann} and Thomas Burke and Lu, {Karen H.} and Ramondetta, {Lois M.}",
year = "2005",
month = "7",
doi = "10.1016/j.ygyno.2005.03.033",
language = "English (US)",
volume = "98",
pages = "77--83",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Practice patterns of SGO members for stage IIIA endometrial cancer

AU - Lee, Christine M.

AU - Slomovitz, Brian

AU - Greer, Marilyn

AU - Sharma, Sheena

AU - Gregurich, Mary Ann

AU - Burke, Thomas

AU - Lu, Karen H.

AU - Ramondetta, Lois M.

PY - 2005/7

Y1 - 2005/7

N2 - Objective. The purpose of surgical staging is to better determine prognosis and treatment. The International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer is a heterogenous disease, and adjuvant therapy is not well-defined. The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer. Methods. All 850 members of the SGO were mailed surveys that asked how they would manage various case scenarios of stage IIIA endometrial cancer. Data were collected using an Internet survey database. Frequency distributions were determined, and nonparametric tests were performed. Results. Fifty-three percent of SGO members and fellows responded. For the treatment of stage IIIA disease with malignant cytology only, adjuvant therapy was recommended 46%, 62%, and 98% of the time for women with grades 1, 2, and UPSC, respectively. Sixty-six percent of respondents would not remove malignant cytology from the current staging criteria. Ninety-nine percent of respondents recommended adjuvant therapy for patients with adnexal or serosal involvement. Eighty-six percent indicated that a hysteroscopy for diagnosis would not alter their treatment recommendations. Conclusions. While most gynecologic oncologists in our survey recommend adjuvant therapy for stage IIIA endometrial carcinoma, our results showed that patients with malignant cytology only would receive different treatments than patients with adenxal or serosal involvement. Histology and grade of the tumor are predictors of therapy recommendations over malignant cytology. Most respondents agreed that patients with malignant cytology should remain in stage IIIA.

AB - Objective. The purpose of surgical staging is to better determine prognosis and treatment. The International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer is a heterogenous disease, and adjuvant therapy is not well-defined. The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer. Methods. All 850 members of the SGO were mailed surveys that asked how they would manage various case scenarios of stage IIIA endometrial cancer. Data were collected using an Internet survey database. Frequency distributions were determined, and nonparametric tests were performed. Results. Fifty-three percent of SGO members and fellows responded. For the treatment of stage IIIA disease with malignant cytology only, adjuvant therapy was recommended 46%, 62%, and 98% of the time for women with grades 1, 2, and UPSC, respectively. Sixty-six percent of respondents would not remove malignant cytology from the current staging criteria. Ninety-nine percent of respondents recommended adjuvant therapy for patients with adnexal or serosal involvement. Eighty-six percent indicated that a hysteroscopy for diagnosis would not alter their treatment recommendations. Conclusions. While most gynecologic oncologists in our survey recommend adjuvant therapy for stage IIIA endometrial carcinoma, our results showed that patients with malignant cytology only would receive different treatments than patients with adenxal or serosal involvement. Histology and grade of the tumor are predictors of therapy recommendations over malignant cytology. Most respondents agreed that patients with malignant cytology should remain in stage IIIA.

KW - Adjuvant therapy

KW - Cytology

KW - Endometrial cancer

KW - Stage IIIA

UR - http://www.scopus.com/inward/record.url?scp=20444486086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444486086&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.03.033

DO - 10.1016/j.ygyno.2005.03.033

M3 - Article

C2 - 15907988

AN - SCOPUS:20444486086

VL - 98

SP - 77

EP - 83

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -